Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05063162 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

Study acronym: cosMOG
StatusActive, Not Recruiting
PhasePhase 3
Started2022-02-02
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 76 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

2026-08-26
Study Status, Contacts/Locations v75
Study sitesdetails revised at 1 of 55 sites
2026-08-13
3 amendments v72-v74
3 re-verifications since 2026-07-02, no change to tracked fields
2026-06-18
Study Status, Contacts/Locations v71
Study sitesdetails revised at 1 of 55 sites
2026-05-21
Study Status, Contacts/Locations v70
Trial sites reduced: 73 → 55 locations
2026-04-24
Study Identification, Study Status, Study Description, Conditions, Study Design, Outcome Measures, Eligibility v69
Enrollment targetestimated 104→confirmed 113
Eligibility criteria-3 characters
[...] time of signing the informed consent Confirmed diagnosis of MOG-ADMOGAD consistent with published diagnostic criteria for MOG-ADMOGAD Participant has history of relapsing MOG-ADMOGAD with at least 1 documented relapse over the last 12 months [...]
Secondary endpoints5 entries, revised
For Part A: Number of MOG-ADMOGAD related inpatient hospitalizations during the DB Treatment Period
Study title-1 characters
[...] odendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-ADMOGAD)
Show 43 earlier versions
2026-03-12
Study Status v68
Re-verified, no change to tracked fields
2026-02-26
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v67
Trial statusRecruiting→Active, Not Recruiting
Study sites83→73
2026-02-12
Study Status, Contacts/Locations v66
Study sitesdetails revised at 2 of 83 sites
2025-12-18
Study Status, Contacts/Locations v65
Study sites82→83
2025-12-04
Study Status v64
Re-verified, no change to tracked fields
2025-11-20
Study Status, Contacts/Locations v63
Study sites81→82
2025-11-06
Study Status, Contacts/Locations v62
Study sites80→81
2025-10-23
Study Status, Contacts/Locations v61
Study sitesdetails revised at 5 of 80 sites
2025-08-14
Study Status, Contacts/Locations v60
Study sites79→80
2025-07-31
Study Status, Contacts/Locations v59
Study sitesdetails revised at 3 of 79 sites
2025-07-17
Study Status, Contacts/Locations v58
Study sitesdetails revised at 1 of 79 sites
2025-07-03
Study Status, Contacts/Locations v57
Study sites77→79
2025-06-05
Study Status v56
Re-verified, no change to tracked fields
2025-05-22
Study Status, Contacts/Locations v55
Study sitesdetails revised at 6 of 77 sites
2025-04-24
Study Status, Contacts/Locations v54
Study sites76→77
2025-04-10
Study Status, Contacts/Locations v53
Study sites75→76
2025-03-27
Study Status, Contacts/Locations v52
Study sites74→75
2025-03-12
Study Status, Contacts/Locations v51
Study sitesdetails revised at 1 of 74 sites
2025-02-27
Study Status, Contacts/Locations v50
Study sites72→74
2025-02-13
Study Identification, Study Status, Contacts/Locations v49
Study sitesdetails revised at 1 of 72 sites
2025-01-30
Study Identification, Study Status, Contacts/Locations v48
Study sites71→72
2024-12-05
Study Status, Contacts/Locations v47
Study sites70→71
2024-11-21
Study Status v46
Re-verified, no change to tracked fields
2024-11-07
Study Status, Contacts/Locations v45
Study sites69→70
2024-10-24
Study Status, Contacts/Locations v44
Study sites68→69
2024-10-10
Study Status, Contacts/Locations v43
Study sites67→68
2024-09-12
Study Status, Contacts/Locations v42
Primary completion date2026-08-10→2027-05-06
Completion date2026-10-05→2027-07-01
Study sites66→67
2024-08-01
Study Status, Contacts/Locations v41
Study sites65→66
2024-06-20
Study Status, Contacts/Locations v40
Study sites64→65
2024-05-23
Study Status, Contacts/Locations v39
Study sites63→64
2024-05-09
Study Status, Contacts/Locations v38
Study sites62→63
2024-04-25
Study Status, Contacts/Locations v37
Study sites60→62
2024-04-11
Study Status, Contacts/Locations v36
Study sites59→60
2024-03-28
Study Status, Contacts/Locations v35
Study sites56→59
2024-03-14
Study Status v34
Re-verified, no change to tracked fields
2024-02-15
Study Status, Contacts/Locations v33
Study sites55→56
2024-02-01
Study Status, Contacts/Locations v32
Study sites53→55
2023-12-19
Study Status, Contacts/Locations v31
Study sites51→53
2023-12-07
Study Status, Contacts/Locations v30
Study sites50→51
2023-12-04
Study Status, Conditions v29
Re-verified, no change to tracked fields
2023-10-12
Study Status, Contacts/Locations v28
Study sitesdetails revised at 1 of 50 sites
2023-09-28
Study Status, Contacts/Locations v27
Study sites49→50
2023-08-17
Study Status, Contacts/Locations v26
Study sites47→49
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD).
Trial Details
NCT Number NCT05063162
Lead Sponsor UCB Biopharma SRL
Conditions Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
Enrollment 113 participants
Start Date 2022-02-02
Primary Completion 2027-05-06 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-25